SCHEMBL4975823

SCHEMBL4975823

CC(C)(C)OC(=O)N1CCC2(CC1)C(=O)Nc1ccc(F)cc12

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IP6K1 Q92551 5/20 0.45
IP6K3 Q96PC2 1/20 0.45
IP6K2 Q9UHH9 1/20 0.45
HDAC2 Q92769 2/20 0.45
HDAC1 Q13547 1/20 0.45
PLK1 P53350 1/20 0.43
PARP1 P09874 4/20 0.41
TNKS O95271 2/20 0.41
TNKS2 Q9H2K2 2/20 0.41
NR1H2 P55055 3/20 0.41
RXRA P19793 2/20 0.41
NR1H3 Q13133 2/20 0.41
CRBN Q96SW2 1/20 0.40
PDK2 Q15119 1/20 0.40
IDO1 P14902 1/20 0.40
TDO2 P48775 1/20 0.40
IDO2 Q6ZQW0 1/20 0.40
KDM4E B2RXH2 1/20 0.40
MAPT P10636 1/20 0.40
THRB P10828 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4975818 1.00 IP6K1 (0.45) IP6K1IP6K3IP6K2HDAC2HDAC1
SCHEMBL23648712 0.91 HDAC2 (0.45) HDAC2HDAC1PLK1PARP1TNKS
SCHEMBL23648688 0.88 CYP1A2 (0.41) HDAC2HDAC1PLK1PARP1NR1H2
SCHEMBL3728233 0.87 HDAC2 (0.40) HDAC2HDAC1PLK1PARP1TNKS
SCHEMBL30507206 0.86 ADRA2B (0.47) IP6K1IP6K3IP6K2NR1H2RXRA
SCHEMBL23648571 0.86 IP6K1 (0.55) IP6K1IP6K3IP6K2IDO1
SCHEMBL13310616 0.86 ADRA2B (0.47) IP6K1IP6K3IP6K2NR1H2RXRA
SCHEMBL25316224 0.86 IP6K1 (0.43) IP6K1IP6K3IP6K2PARP1TNKS
SCHEMBL30506924 0.86 IP6K1 (0.43) IP6K1IP6K3IP6K2PARP1TNKS
SCHEMBL4268010 0.85 ALDH1A1 (0.47) IP6K1IP6K3IP6K2NR1H2RXRA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7354925-B2 Alpha aryl or heteroaryl methyl beta piperidino propanamide compounds as ORL1-receptor antagonists PFIZER INC. (US) 2008-04-08 US disclosed
US-7279486-B2 Alpha aryl or heteroaryl methyl beta piperidino propanoic acid compounds as ORL1-receptor antagonists PFIZER INC. (US) 2007-10-09 US disclosed
US-20070197500-A1 3-(2,3-Dihydro-1'H-spiro[indene-1,4'-piperidin]-1'-yl)-N,N-dimethyl-2-(pyridin-2-ylmethyl)propanamide; opioid receptor-like 1 antagonist; reduced inhibitory activity at HERG potassium channel; analgesic; side effect reduction; neurpathic and other pain PFIZER, INC. 2007-08-23 US disclosed
EP-1732928-A2 ALPHA ARYL OR HETEROARYL METHYL BETA PIPERIDINO PROPANOIC ACID COMPOUNDS AS ORL1-RECEPTOR ANTAGONISTS Pfizer, Inc. (US) 2006-12-20 EP disclosed
US-20050277659-A1 Alpha aryl or heteroaryl methyl beta piperidino propanoic acid compounds as ORL1-receptor antagonists PFIZER JAPAN INC. (JP) 2005-12-15 US disclosed
WO-2005092895-A2 ALPHA ARYL OR HETEROARYL METHYL BETA PIPERIDINO PROPANOIC ACID COMPOUNDS AS ORL1-RECEPTOR ANTAGONISTS PFIZER JAPAN INC. (JP) 2005-10-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050277659-A1 Alpha aryl or heteroaryl methyl beta piperidino propanoic acid compounds as ORL1-receptor antagonists OPRL1, OGFRL1, ORMDL3 IP6K1 1515/4885IP6K3 2306/4885IP6K2 2221/4885
US-20070197500-A1 3-(2,3-Dihydro-1'H-spiro[indene-1,4'-piperidin]-1'-yl)-N,N-dimethyl-2-(pyridin-2-ylmethyl)propanamide; opioid receptor-like 1 antagonist; reduced inhibitory activity at HERG potassium channel; analgesic; side effect reduction; neurpathic and other pain OPRL1, OPRD1, OPRK1 IP6K1 657/4885IP6K3 1240/4885IP6K2 938/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.